Respiratory Conditions

NHS prescribing intelligence on inhalers, spacers, drugs and other devices used in asthma and COPD

Treatment of respiratory conditions represents a significant part of UK community prescribing, by spend and by number of prescription items. Nearly 12% of spend in England in 2017 and 6.5% of prescription items related to the respiratory system (BNF chapter 3). Two of the top ten BNF sections when ranked by net ingredient cost are therapies for respiratory conditions; corticosteroids is the second highest section in terms of spend and bronchodilators is the seventh highest.



therapy-area

Additional resources on prescribing for respiratory conditions

Please see below for some of GPrX's content relating to respiratory conditions


Further Resources:

Other industry sectors Free useful downloads